A spin-off from from Fraunhofer Institute for Immune Pathology and Immune Tolerance, Phialogics is a preclinical biotech company specializing in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed …

Enthera is a biotech company building a pipeline of first-in-class biologics for several underserved autoimmune conditions, with a focus on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). It aims to develop disease-modifying treatments by preserving and re-establishing cell and organ function to revert the outcome of these conditions. Enthera’s therapeutics are founded on …